Paclitaxel is a chemotherapeutic agent for the treatment of advanced solid carcinomas, such as breast, ovaries, lung, and head and neck.
In Vitro Cytotoxicity of HFT-T

Cytotoxic activity of free paclitaxel , HT-T and HFT-T nanoparticles were compared.
A colony formation assay was performed using the human head and neck cancer cell lines KB-3-1 (with folic acid receptor) and Tu212 (no folic acid receptor). Cells were exposed to 2.5 nM paclitaxel and the HFT-T and HT-T nanoparticles at a paclitaxelequivalent dose of 2.5 nM. Forty-eight hours after injection, the liver, kidney, lung, heart, and spleen were collected, and all tissues were analyzed by fluorescence imaging. For both HFT-T and HT-T, the greatest fluorescence intensity was observed in the tumor compared with the other tissues. Although the signal intensity in tumor tissue was slightly higher for HFT-T than HT-T, the difference was not significant. (i.v.) . HFT-T showed marked internalization in KB-3-1 cells identified by human EpCAM expression (green). In contrast, HT-T showed much less internalization by KB-3-1 cells and was predominantly found in the extracellular space. 
To check whether HFT-T and HT-T nanoparticles simply
. In vivo distribution of HFT-T in KB-3-1 tumor-bearing mice. Near infrared dye (cy5.5)-labeled HFT-T or HT-T was injected i.v. into KB-3-1 tumor-bearing mice. (a) Imaging of mice at 1, 24, and 48 h after injection. (b) Biodistribution of HFT-T and HT-T in major organs at 48 h after injection. (c) The cellular internalization of HFT-T versus HT-T in KB-3-1 xenografts 24 h after injection
This is strong evidence that HFT-T is much more effective than free paclitaxel in treating tumors
and is less susceptible to drug resistance, which is a very common occurrence in patients clinically treated with paclitaxel.
